The Five Revenue Streams That Run Through Every PBM Contract — and Five Needed Reforms

Key Takeaways

• Five hidden PBM revenue streams drive most prescription drug costs.
• Spread pricing masks markup between plan sponsor payments and pharmacy reimbursements.
• Rebate retention and manufacturer-direct payments keep rebates away from plan sponsors.
• Owned‑pharmacy margin steers specialty drugs to PBM‑owned pharmacies for extra profit.
• Proposed reforms call for disclosure, firewalling, and side‑by‑side cost comparisons.

Pulse Analysis

Pharmacy Benefit Managers have become the gatekeepers of prescription drug spending, but their business model is riddled with opaque profit centers. Beyond the modest administrative fee that appears on invoices, PBMs extract value through spread pricing—charging employers a higher price than they reimburse pharmacies—and by retaining rebates that manufacturers pay for formulary placement. Additional cash flows come from manufacturer‑direct payments for data licensing or educational services, and from the margin earned when PBM‑owned pharmacies dispense specialty drugs. These layers of hidden revenue make it difficult for plan sponsors to assess true drug costs, prompting calls for greater transparency.

Regulators have traditionally targeted one stream at a time, such as banning spread pricing or mandating rebate pass‑through. However, the article demonstrates that when one lever is pulled, PBMs simply shift profit to another unregulated channel, preserving overall margins. The proposed five‑point reform agenda seeks to close these loopholes: mandatory drug‑level markup disclosure, firewalls separating pricing decisions from pharmacy ownership, comprehensive rebate reporting, clear rules on copay accumulator programs, and side‑by‑side cost comparisons for medical versus pharmacy billing. Implementing these measures would give employers the data needed to negotiate better contracts and could force PBMs to compete on price rather than proprietary profit mechanisms.

For the broader health‑care market, structural reform of PBM contracts could unlock significant savings for self‑funded employers and, by extension, for employees who bear a portion of drug costs. Greater transparency would also level competition among PBMs, encouraging innovation in benefit design and clinical management rather than reliance on hidden fees. As policymakers consider these reforms, stakeholders—from insurers to drug manufacturers—must adapt to a more open ecosystem where pricing is visible, auditable, and ultimately, more aligned with the goal of affordable access to essential medicines.